Finally, we analyzed associations between the transcriptional levels of CDKN2A and its two targets CDK4 and CDK6 with overall survival (OS) for mUC and NSCLC, and progression-free survival (PFS) in RCC (Fig. 4d). Here, CDKN2A is linked to non-small cell lung carcinoma.